CD226 and melanoma: Foxp3+ Tregs are well known to be suppressive components of the adaptive immune response, and recent data in melanoma has demonstrated that Tregs exhibit increased expression of TIGIT, and decreased expression of its competing costimulatory receptor DNAM-1 as compared with CD4+ T cells resulting in an increased TIGIT/DNAM-1 ratio.